Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Brandon May

    News

    Guselkumab found promising for Crohn’s in phase 2 study

    Author:
    Brandon May
    Publish date: April 1, 2022

    Conventional first-line therapies for Crohn’s disease often are not effective for maintaining clinical remission and are associated with...

    • Read More

    News

    Registry data support lowering CRC screening age to 45

    Author:
    Brandon May
    Publish date: March 15, 2022

    Existing research gaps on the rates of younger-onset colorectal neoplasia need to be addressed to support these recommendations.

    • Read More

    News

    Cryoballoon ablation demonstrates long-term durability in BE

    Author:
    Brandon May
    Publish date: March 15, 2022

    Despite its utility, few data are available to describe the durability of the cryoballoon ablation’s effects for Barrett’s esophagus.

    • Read More

    News

    Registry data support lowering CRC screening age to 45

    Author:
    Brandon May
    Publish date: March 15, 2022

    Existing research gaps on the rates of younger-onset colorectal neoplasia need to be addressed to support these recommendations.

    • Read More

    News

    Improved follow-up needed to find late-stage pancreatic cancers

    Author:
    Brandon May
    Publish date: February 10, 2022

    Factors associated with detecting late-stage pancreatic ductal adenocarcinomas during this follow-up are hard to pin down.

    • Read More

    News

    Improved follow-up needed to find late-stage pancreatic cancers

    Author:
    Brandon May
    Publish date: February 4, 2022

    Factors associated with detecting late-stage pancreatic ductal adenocarcinomas during this follow-up are hard to pin down.

    • Read More

    News

    ACE index predicts steroid response in acute severe UC

    Author:
    Brandon May
    Publish date: January 5, 2022

    The ACE index shows promise for earlier prediction of steroid nonresponse in patients with acute severe UC.

    • Read More

    News

    Real-world practice informs tofacitinib use in UC

    Author:
    Brandon May
    Publish date: January 5, 2022

    Real-world data and practice observations provide further insight into the effective use of the JAK inhibitor in moderate-to-severe UC.

    • Read More

    News

    Vedolizumab does not increase risk of C. diff infection in UC

    Author:
    Brandon May
    Publish date: January 3, 2022

    Vedolizumab’s effects in the intestines have led to concerns that the antibody could increase the risk of C. difficile infection in...

    • Read More

    News

    Vedolizumab does not increase risk of C. diff infection in UC

    Author:
    Brandon May
    Publish date: December 27, 2021

    Vedolizumab’s effects in the intestines have led to concerns that the antibody could increase the risk of C. difficile infection in...

    • Read More

    News

    Few patients with IBD receive early vedolizumab

    Author:
    Brandon May
    Publish date: December 27, 2021

    Earlier treatment is associated with increased likelihood of response and remission, but in clinical practice, biologic agents are often delayed...

    • Read More

    News

    AI system improves early gastric cancer detection

    Author:
    Brandon May
    Publish date: December 27, 2021

    Gastric cancer detection practices vary considerably across providers, creating the need for objective, consistent approaches to earlier detection...

    • Read More

    News

    Hemostatic powder noninferior in nonvariceal upper GI bleeds

    Author:
    Brandon May
    Publish date: December 6, 2021

    TC-325 hemostatic powder compares well with standard endoscopic treatment of acute nonvariceal gastrointestinal bleeding in a new study.

    • Read More

    News

    ESD vs. cEMR: Rates of complete remission in Barrett’s compared

    Author:
    Brandon May
    Publish date: December 1, 2021

    The study found similar rates of complete remission of intestinal metaplasia between the ESD and cEMR treatment groups at 2 years.

    • Read More

    News

    COVID-19 vaccines: Lower serologic response among IBD, rheumatic diseases

    Author:
    Brandon May
    Publish date: December 1, 2021

    Patients with immune-mediated inflammatory diseases urged to get full mRNA vaccine series without delay and possibly a third dose.

    • Read More

    Pages

    • « first
    • 1
    • 2
    • 3
    • 4
    • 5
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery